Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma

Therapeutic Drug Monitoring

Volumn 30, Issue 5, 2008, Pages 620-627

  Liu, Qing ^a   Parley, Katherine L ^b   Johnson, Amy J ^c   Muthusamy, Natarajan ^c   Hojmeister, Craig C ^c   Blum, Kristie A ^c   Schaaf, Larry J ^a,b   Grever, Michael R ^b,c   Byrd, John C ^b,c,d   Dalton, James T ^a,b   Phelps, Mitch A ^b,e  

^a Division of Pharmaceutics College of Pharmacy

^b Comprehensive Cancer Center ^*

^c Division of Hematology Oncology Department of Internal Medicine

^d OHIO STATE UNIVERSITY   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

Flavopiridol; Lenalidomide; Liquid chromatography mass spectometry (LC MS); Pharmacokinetics

Indexed keywords

ACETONITRILE; FLAVOPIRIDOL; FORMIC ACID; GENISTEIN; LENALIDOMIDE; TEMSIROLIMUS; FLAVONOID; PIPERIDINE DERIVATIVE; THALIDOMIDE;

ANIMAL EXPERIMENT; ARTICLE; ATMOSPHERIC PRESSURE; CHEMICAL REACTION; CHRONIC MYELOID LEUKEMIA; DRUG BLOOD LEVEL; DRUG STRUCTURE; EVAPORATION; HUMAN; IONIZATION; LIQUID LIQUID EXTRACTION; LOW DRUG DOSE; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; STANDARD; TANDEM MASS SPECTROMETRY; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; ELECTROSPRAY MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; MULTIPLE MYELOMA; PROCEDURES; RECURRENT DISEASE; STANDARDS; TIME; VALIDATION STUDY;

CHROMATOGRAPHY, LIQUID; FLAVONOIDS; HUMANS; MULTIPLE MYELOMA; PIPERIDINES; RECURRENCE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THALIDOMIDE; TIME FACTORS;

EID: 55349093022     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318185813d     Document Type: Article

References (21)

1. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15:1950-1961.
2. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943-2950.
3. Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380-386.
4. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
5. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456-1465.
6. Patel PH, Kondagunta GV, Schwartz L, et al. Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Invest New Drugs. 2008; 26:273-276.
7. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067.
8. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343-5349.
9. Ferrajoli A, Faderl S, Ravandi F, et al. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets. 2006;6:671-679.
10. Andritsos LA, Johnson AJ, Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol. 2008;26:2519-2525.
11. Pepper C, Thomas A, Fegan C, et al. Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism. Leuk Lymphoma. 2003;44:337-342.
12. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res. 2002;8:3527-3538.
13. Rosato RR, Almenara JA, Kolla SS, et al. Mechanism and functional role of XIAP and Mcl-I down-regulation in flavopiridol/vorinostat antileukemic interactions. Mol Cancer Ther. 2007;6:692-702.
14. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood. 2007;109:399-404.
15. Tohnya TM, Hwang K, Lepper ER, et al. Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatographymass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;811:135-141.
16. Chen N, Lau H, Kong L, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol. 2007;47:1466-1475.
17. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry-on Bioanalytical Method Validation. Department of Health and Human Services; Rockville, MD: 2001.
18. Phelps MA, Rozewski DM, Johnston JS, et al. Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;868:110-115.
19. Saravanan G, Rao BM, Ravikumar M, et al. Development of an HPLC assay method for lenalidomide. Chromatographia. 2007;66:287-290.
20. Stinson SF, Hill K, Siford TJ, et al. Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection. Cancer Chemother Pharmacol. 1998;42:261-265.
21. Zhai SP, Sausville E, Figg WD. A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma. Biomed Chromatogr. 2002;16:379-382.